the role of testin and serum test in women breast cancer

Background & objective: in 2020, breast cancer claimed the lives of approximately 684,996 women worldwide. the use of cancer biomarkers has greatly improved the effectiveness of treatment and early detection. the present study was conducted aimed to identify the role of testin as a potential biomarker in women with breast cancer. materials & methods: in this cross-sectional study, 60 women with breast cancer participated by providing serum samples for measuring testin concentrations. additionally, a control group of 20 healthy individuals was selected. the testin protein concentration was detected using the serum elisa method. results: a significant difference was observed between the age groups of patients and healthy women. the majority of women with breast cancer were in their thirties to sixties. on the other hand, there were fewer breast cancer cases recorded in the twenties, with only 1 (1.7%) case out of the total study population of 60 (100%). this difference was found to be statistically significant (p=0.01). the study found that there was no significant difference in the concentration of testin among women with breast cancer who were newly diagnosed compared to those who had received different numbers of treatment doses (1, 3, 5, 7 doses). also, the results indicated a significant increase in testin concentration among women with breast cancer compare with healthy women. conclusion: the present study discovered that breast cancer patients have higher levels of testin compared to the healthy women. there is a growing body of evidence suggesting that testin contributes to the development of breast cancer, making it an appealing protein to focus on for cancer treatment.